Pacific Biosciences of California Beheer

Beheer criteriumcontroles 2/4

De CEO Pacific Biosciences of California is Christian O. Henry, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.05M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde € 660.30K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 11.8 jaar.

Belangrijke informatie

Christian O. Henry

Algemeen directeur

US$8.0m

Totale compensatie

Percentage CEO-salaris	8.6%
Dienstverband CEO	4.2yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	4.2yrs
Gemiddelde ambtstermijn bestuur	11.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Christian O. Henry's beloning veranderd ten opzichte van Pacific Biosciences of California's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$394m
Jun 30 2024	n/a	n/a	-US$400m
Mar 31 2024	n/a	n/a	-US$297m
Dec 31 2023	US$8m	US$695k	-US$307m
Sep 30 2023	n/a	n/a	-US$309m
Jun 30 2023	n/a	n/a	-US$319m
Mar 31 2023	n/a	n/a	-US$321m
Dec 31 2022	US$7m	US$667k	-US$314m
Sep 30 2022	n/a	n/a	-US$299m
Jun 30 2022	n/a	n/a	-US$206m
Mar 31 2022	n/a	n/a	-US$175m
Dec 31 2021	US$3m	US$650k	-US$181m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$59m
Dec 31 2020	US$13m	US$195k	US$29m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$51m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$100k	n/a	-US$84m
Sep 30 2019	n/a	n/a	-US$115m
Jun 30 2019	n/a	n/a	-US$111m
Mar 31 2019	n/a	n/a	-US$109m
Dec 31 2018	US$88k	n/a	-US$103m

Compensatie versus markt: De totale vergoeding ($USD 8.05M ) Christian O. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.03M ).

Compensatie versus inkomsten: De vergoeding van Christian O. is gestegen terwijl het bedrijf verliesgevend is.

CEO

Christian O. Henry (56 yo)

4.2yrs

Tenure

US$8,046,575

Compensatie

Mr. Christian O. Henry, MBA, served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He has been President and Chief Executive Officer at Pacific Biosciences o...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christian O. Henry	President	4.2yrs	US$8.05m	0.14% € 660.3k
Susan Kim	Chief Financial Officer	4.2yrs	US$2.52m	0.043% € 201.0k
Mark Van Oene	Chief Operating Officer	3.8yrs	US$4.60m	0.12% € 537.7k
Stephen Turner	Co-Founder	24.3yrs	US$466.76k	geen gegevens
Michele Farmer	VP & Chief Accounting Officer	3.5yrs	geen gegevens	0.013% € 61.6k
Brett Atkins	General Counsel & Corporate Secretary	no data	geen gegevens	geen gegevens
Natalie Welch	Chief People Officer	no data	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van P09 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christian O. Henry	President	6.3yrs	US$8.05m	0.14% € 660.3k
William Ericson	Independent Director	20.8yrs	US$259.00k	0.0069% € 31.9k
Lucy Shapiro	Independent Director	12.2yrs	US$255.00k	0% € 0
John Milligan	Independent Chairman	11.3yrs	US$297.00k	0.040% € 187.0k
Harry Gray	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Joseph Bonventre	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Randall Livingston	Independent Director	15.8yrs	US$265.00k	0% € 0
Harold Craighead	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roger Kornberg	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Watt Webb	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kenneth Johnson	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jay Shendure	Chairman of Scientific Advisory Board	2yrs	geen gegevens	geen gegevens

11.8yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van P09 zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

Pacific Biosciences of California Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Insider recently bought €162k worth of stock

President recently sold €445k worth of stock

Chief Operating Officer recently sold €221k worth of stock

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.26 loss in 3Q 2023)

PacBio Unveils the Vega System

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems

Pacific Biosciences of California, Inc. to Report Q3, 2024 Results on Nov 07, 2024

President recently sold €155k worth of stock

Chief Operating Officer recently sold €57k worth of stock

Pacific Biosciences of California, Inc. Reports Goodwill Impairment for the Second Quarter Ended June 30, 2024

Pacific Biosciences of California, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.36 loss in 1Q 2023)

Pacific Biosciences of California, Inc., Annual General Meeting, Jun 18, 2024

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought €162k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

President recently sold €445k worth of stock

Full year 2023 earnings released: US$1.21 loss per share (vs US$1.40 loss in FY 2022)

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold €221k worth of stock

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Third quarter 2023 earnings released: US$0.26 loss per share (vs US$0.34 loss in 3Q 2022)

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold €918k worth of stock

Chief Operating Officer recently sold €263k worth of stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.32 loss in 2Q 2022)

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Now 25% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

VP & Chief Accounting Officer recently sold €60k worth of stock

Insufficient new directors

Full year 2022 earnings released: US$1.40 loss per share (vs US$0.89 loss in FY 2021)

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold €75k worth of stock

PacBio Unveils A New Method for Comprehensive, Genome-Wide Tandem Repeat Analysis

Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.21 loss in 2Q 2021)

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Full Year 2022

Pacific Biosciences of California, Inc. Appoints Jeff Eidel as Chief Commercial Officer, Effective August 16, 2022

Pacific Biosciences of California, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacific Biosciences of California, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.45 loss in 1Q 2021)

Insufficient new directors

Pacific Biosciences of California, Inc. to Report Q1, 2022 Results on May 04, 2022

Pacific Biosciences of California, Inc., Annual General Meeting, May 25, 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Pacific Biosciences of California, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Chief Operating Officer recently sold €519k worth of stock

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Fourth Quarter and the Fiscal Year Ended December 31, 2021

PacBio’s New HiFiViral Surveillance Kit Performance is Not Impacted by Omicron Mutations, Delivering Complete SARS-CoV-2 Genomes for All Circulating Variants

Insufficient new directors